The TopCSPN trial is a double blinded randomized placebo controlled study of oral topiramate
as a potential disease altering therapy for cryptogenic sensory peripheral neuropathy (CSPN).
Patients with CSPN who also have metabolic syndrome (defined by the ATPIII criteria) who do
not have an alternative cause for neuropathy will be potentially eligible. The co primary
outcome measures are change in the Norfolk Quality of Life - Diabetic Neuropathy (NQOL-DN)
Scale and intraepidermal nerve fiber density (IEFND) at the distal thigh. The treatment phase
will last 24 months.

This is a prospective observational study of 30 adult CIDP patients who receive home IVIg
infusion services from AxelaCare Health Solutions, LLC. The decision to treat with IVIg
will be entirely at the discretion of the patient's treating physician.